Facilitating Technology Transfer to LMICs

New Challenges, Paradigms and Opportunities

DCVMN AGM 20th October 2021

Raman Rao, MD
Chief Executive Officer,
Hilleman Laboratories, Singapore.
Four dimensions of an effective global Immunisation strategy

- **Development and production**
  - Vaccines authorised by stringent regulatory bodies or WHO
  - Production at scale

- **Affordability**
  - Prices reflecting public investment and risk-sharing, taking into account large volume of purchases
  - Sustainable funding for COVID-19 vaccines and vaccination programmes

- **Allocation**
  - Availability of vaccines where needed
  - Support for multilateral initiatives to ensure timely global access

- **Deployment**
  - Infrastructure enabling efficient distribution and administration of doses, regionally and locally
  - Public confidence in vaccines and vaccination programmes to achieve widespread uptake
Tech Transfer Strategies and Implications

- Technology transfer to developing countries has contributed significantly to increasing vaccine supply, and access to many vaccines including pricing.
- Dynamism in vaccine technology transfer modalities, with joint ventures, acquisitions and establishment by multinational manufacturers of subsidiaries in developing countries becoming more frequent.
- The establishment of research-based entities developing and providing new vaccines and Bridging platforms.

---

**Increasing Access to Vaccines Through Technology Transfer and Local Production**

*World Health Organization 2011*
Innovative Technology Transfer Mechanism and Challanges

• Opportunities

  • Manufacturing and formulation **Platform** innovations to reduce Cost of Goods (COGS) and facilitate process transfer
    • Flexible, modular facility, disposables, integrated ‘continuous’ processes
  • Enhancing R&D and technological and manufacturing capabilities in developing countries (esp. new platforms e.g. mRNA vaccines) through Tech transfer Hubs.
  • Novel IP access modalities e.g. IPTK bank*, Hubs.

• Challenges

  • R&D capacity
  • Human Resources and lack of experience.
  • Evaluation and assessment of technologies.
  • Existing Hub Model & New Vaccines: Know-How
  • Business case/sustainability
  • Government facilitation & Investment.

Thank you